Results 241 to 250 of about 3,265,963 (321)
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan +6 more
wiley +1 more source
Clinical Trials With Pragmatic Elements: A Review of Use Cases and Real‐World Data Utilization
Clinical trials with pragmatic elements can capture diverse patient populations, enable efficient follow‐up, and reflect routine clinical practices; yet there is limited understanding of their design features, characteristics, and use of real‐world data (RWD). Based on a targeted search of PubMed/EMBASE (Jan‐2016 to Jul‐2024), a review was conducted to
Le Su +6 more
wiley +1 more source
Antiangiogenic therapy with bevacizumab improves outcomes in ovarian cancer but induces hypertension, leading to major adverse cardiovascular events (MACE). While calcium channel blockers (CCBs) and angiotensin‐converting enzyme inhibitors (ACEi) are recommended for managing bevacizumab‐associated hypertension, their impacts on cancer progression and ...
Floriane Jochum +10 more
wiley +1 more source
Editorial: Recent advances on the multimodal search for markers of treatment response in affective disorders: from bench to bedside, volume II. [PDF]
Walter M +5 more
europepmc +1 more source
Assessing the relationship between suicidality and inflammatory biomarkers: C-reactive protein/albumin and neutrophil/albumin ratios in an inpatient setting. [PDF]
Elbay RY, Erdil SS, İlhan AH.
europepmc +1 more source
Biological rehabilitation: A necessary next step in clinical psychiatry and neuroscience research
M. Faria
openalex +1 more source

